lyophilisation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-14. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Ablukast (INN) is an experimental drug that is a leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease. It reached Phase III clinical trials, but development was discontinued in 1996.
The other settings were available to block out interference, but did so by also blocking some of the signal which reduced the overall sensitivity of the system. The output of the mixer was sent to the Y-axis deflection plates in a specially designed high-quality CRT. For reasons not well explained in the literature, this was arranged to deflect the beam downward with increasing signal. When combined with the X-axis signal from the time base generator, echoes received from distant objects caused the display to produce blips along the display. By measuring the centre point of the blip against a mechanical scale along the top of the display, the range to the target could be determined. This measurement was later aided by the addition of the calibrator unit or strobe, which caused additional sharp blips to be drawn every 10 miles (16 km) along the display. The markers were fed from the same electronic signals as the time base, so it was always properly calibrated.
With a population of 84.7 million according to the 2023 German census, Germany is the most populous member state of the European Union, the second-most populous country in Europe after Russia, and the nineteenth-most populous country in the world. Its population density stands at 236 inhabitants per square kilometre (610 inhabitants/mi2). The fertility rate of 1.36 children born per woman (2024 estimates) is below the replacement rate of 2.1, but slightly above the EU average of 1.34. Since the 1970s, Germany's death rate has exceeded its birth rate. However, the country is witnessing increased birth and migration rates since the early 2010s. Germany has the fourth oldest population in the world, with an average age of 47.8 years.
Sources: en.wikipedia.org
== Locations of fibrocartilage in the human body == secondary cartilaginous joints: pubic symphysis annulus fibrosis of intervertebral discs manubriosternal joint glenoid labrum of shoulder joint acetabular labrum of hip joint medial and lateral menisci of the knee joint location where tendons and ligaments attach to bone triangular fibrocartilage complex (UTFCC)
=== Brand names === Propranolol was first marketed under the brand name Inderal, manufactured by ICI Pharmaceuticals (now AstraZeneca), in 1965. "Inderal" is a quasi-anagram of "Alderlin", the trade name of pronethalol (which propranolol replaced); both names are an homage to Alderley Park, the ICI headquarters where the drugs were first developed. Propranolol is also sold under the brand names Avlocardyl, Deralin, Dociton, Hemangeol, Inderalici, InnoPran XL, Indoblok, Sumial, Anaprilin, and Bedranol SR (Sandoz). In India, it is sold under brand names such as Ciplar and Ciplar LA by Cipla.
She initially attempts to use her powers on Jasmine, but learns of Jasmine's ESP and tries to make the latter her pet instead. Despite being mortally wounded by Blitz, Succubus dies transferring her lifeforce to him. During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Saunaginnan revives Succubus, who is subsequently deleted by Deka Pink and Yellow and Abare Yellow. Succubus Hells is portrayed by Mayu Gamō (蒲生 麻由, Gamō Mayu). Reversian Blitz Hells (リバーシア星人ブリッツ・ヘルズ, Ribāshia Seijin Burittsu Heruzu): The oldest, cruelest, and most powerful of the Hells Siblings who possesses energy-based powers, wields a sword and a machine gun-like blaster, is willing to sacrifice his siblings, and earned a reputation as the "Outer Space Grim Reaper" (宇宙の死神, Uchū no Shinigami). After being defeated by the Dekarangers, he attempts to escape in God Pounder, only to be deleted by Riding Dekaranger Robo. Blitz Hells is voiced by Hiroshi Tsuchida (土田 大, Tsuchida Hiroshi). Tylerian Durden (タイラー星人ダーデン, Tairā Seijin Dāden): The owner and fight promoter of an illegal fight club, gambling operation, and illegal steroid ring from Planet Tyler. After recognizing the Dekarangers while they were infiltrating his fight club, he retaliates by piloting a demon-themed Kaijuki called Ultimate Evil (アルティメットイビル, Arutimetto Ibiru), only to be deleted by Super Dekaranger Robo. Durden is voiced by Masaharu Satō (佐藤 正治, Satō Masaharu).
Sources: en.wikipedia.org
=== Total synthesis === In 1989 and 1993, Yamada and co-workers reported the first enantioselective total synthesis of both the enantiomers of ptaquilosin, the aglycone of ptaquiloside. In the first step, the menthyl ester of cyclopentane-1,2-dicarboxylic acid 1 was partially hydrolyzed to afford the monomenthyl ester, which was later alkylated with methallyl bromide in the presence of HMPA to selectively produce 2. The product 2 was then converted to the acid chloride and treated with stannic chloride to effect Friedel-Crafts acylation to give enone 3. Hydride reduction, selective oxidation of the allylic alcohol, and silylation were then performed to provide compound 4. On treatment with base and a chloroethyl sulfonium salt, a mixture of spirocyclopropanes was obtained. The minor product 5a can be isomerized with p-toluenesulfonic acid to 5b with 81% yield. Desaturation by selenylation/dehydroselenation and basic peroxide oxidation afforded epoxide 6. Mild reduction, methyl Grignard addition, and oxidation gave compound 7. Methylation of the cyclopentanone under Noyori's condition using the TASF enolate produced a mixture of isomers. The undesired isomer 8a can be equilibriumed with potassium tert-butoxide in 81% yield to exclusively generate 8b. Reduction, deprotection, and oxidation afforded 9. On treatment with oxygen in warm ethyl acetate, the aldehyde on 9 was oxidized to the acyl radical for decarbonylation. Stereoselective trapping of the tertiary radical by oxygen gave the hydroperoxide 10.
Historian Eduardo Torres Cuevas has written:"A question arises during this period: Was it possible that individuals within the island's power structure were linked to Freemasonry? Much remains to be studied in this regard. The fact that, during those years, the Cuban political government, as well as a significant portion of the emerging Havana oligarchy, were closely linked to the Count of Aranda's group in Spain, gave rise to the hypothesis that some of its members were Freemasons and, therefore, held meetings in Cuba... This hypothesis appears to have faded after the work of Dr. José Antonio Ferrer Benimeli, who clarifies the historical enigma of the Count of Aranda as a Freemason."In 1767, in mainland Spain, the Grand Logia Española changed its name to Gran Oriente and was recognized by the Grand Lodge of England.
It has been long observed that the licking of their wounds by dogs might be beneficial. Indeed, a dog's saliva is bactericidal against the bacteria Escherichia coli and Streptococcus canis, although not against coagulase-positive Staphylococcus or Pseudomonas aeruginosa. Wound licking is also important in other animals. Removal of the salivary glands of mice and rats slows wound healing, and communal licking of wounds among rodents accelerates wound healing. Communal licking is common in several primate species. In macaques, hair surrounding a wound and any dirt is removed, and the wound is licked, healing without infection. An Elizabethan collar may be used on pet animals to prevent them from biting an injury or excessively licking it, which can cause a lick granuloma. These lesions are often infected by pathogenic bacteria such as Staphylococcus intermedius. Horses that lick wounds may become infected by a stomach parasite, Habronema, a type of nematode worm. The rabies virus may be transmitted between animals, such as the kudu antelopes by wound licking of wounds with residual infectious saliva.
== Adverse effects == Cetacaine has been known to cause adverse effects in the patients it has been administered to. These include hypersensitivity in the form of anaphylaxis, dermatitis, erythema, pruritus which can lead to oozing and vesiculation. There have also been accounts of rashes, edema, urticarial and other allergic symptoms as well as methemoglobinemia. Other adverse effects can include: tremors, twitching, dizziness, confusion, hypo-tension, vomiting, euphoria, and blurred or double vision.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.